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Psychedelic Research Resurgence
Andrew Demosthenous
receptors. Many hallucinogens are found naturally
in plants and animals. Evolution of tools in
chemistry and the scientific method in the 1900s
supported the process of synthesizing new
hallucinogens.
With the enactment of the Controlled
Substances Act of 1970, hallucinogens, among
them LSD and Psilocybin, were classified as
schedule I drugs by the United States congress
(U.S. Drug Enforcement Agency 2010). In 1984,
MDMA was added by the Drug Enforcement
Agency (Baum 1997, p. 213).The schedule of the
drugs, I being the highest and V being the lowest,
determines the regulatory measures enforced by the
United States DEA. The higher the drug
scheduling, the stricter the policies are regarding
manufacturing, importation, possession,
distribution, and research for that particular drug.
Placing LSD, Psilocybin and MDMA in the
schedule I classification disrupted research on the
application of hallucinogens to well-being and
mental health. This also fostered the strictest
judicial consequences for possession and
distribution. Both using and distributing LSD are
felonies. Anyone caught distributing LSD can get
up to forty years in a federal penitentiary and a two
million dollar fine (National Geographic 2009).
Three criteria the United States DEA and FDA
use for determining if a substance should be
classified as schedule I are: 1) the drug has no
accepted medical use in the United States; 2) there
is a lack of safety for use of the drug under medical
supervision; 3) the substance has a high “potential
for abuse” (Nichols 2003, p. 133). “Potential for
abuse,” an ambiguous criterion, is typically
interpreted by the United States DEA and FDA as
the potential for addiction.
The FDA system of scheduling has been
heavily criticized due to the influence of politics.
President Nixon in the early 1970’s took
responsibility for drug scheduling away from the
Surgeon General and his team of medical experts.
The responsibility was delegated instead to the
office of the attorney general and his team of law
enforcement experts. Since then, “cops and lawyers
instead of doctors were judging the toxicity of
drugs” (Baum 1997, p. 25-26). Decisions made by
the U.S. attorney general’s office regarding the

Introduction
In the 1960s, more than 1,000 peer-reviewed
research articles detailed the therapeutic use of
psychedelic compounds. Passage of the Controlled
Substance Act of 1970 classified psychedelic
substances such as LSD, MDMA and Psilocybin as
Schedule 1 drugs with no medical value,
interrupting research into the application of
psychedelic compounds for well-being. New
studies from institutions such as New York
University, Purdue University, Harvard University,
and Johns Hopkins University are producing
evidence that use of these drugs in combination
with psychotherapy may have potential value for
treating mental illnesses such as addiction, mood,
affective, and psychotic disorders. This study
explores the relationship between the effects of
these drugs on well-being and the FDA scheduling
of these drugs at the highest level. Analyses of six
open-ended interviews with a snowball sample of
college students about their recreational
experiences with LSD, MDMA and Psilocybin
found that college students use these drugs as a tool
for spiritual and emotional development. They
reported positive transformative experiences and
improved relationships with family and friends.
These findings support the continued expansion of
research on psychedelic assisted psychotherapy for
treatment of mental illness and the rescheduling of
medically beneficial psychedelics by the FDA.
Hallucinogens
“Hallucinogens are substances that cause
powerful changes in sensory perception, from
strengthening a person’s normal perceptions to
inducing illusions and hallucinations” (Comer
2010, p. 389). These substances, also known as
psychedelic drugs, include LSD (Lysergic Acid
Diethylamide), Psilocybin (4-phosphoryloxy-N,Ndimethyltryptamine), and MDMA (3,4methylenedioxymethamphetamine). Many people
use different definitions for hallucinogens and
include different types of drugs into those
definitions. For the purpose of this paper, the
hallucinogens being discussed will be the
substances which affect serotonin (5-HT) type
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scheduling of drugs were more heavily influenced
by the politics of the war on drugs than scientific
data presented by doctors. For example, in the
hearings held by the DEA in 1986 regarding the
scheduling of MDMA, thirty-four witnesses,
including experts in the field of psychology and
psychiatry, gave testimony and a ten volume report
outlining the potential medical benefits of MDMA,
asking for its rank to be lowered to schedule III.
DEA Administrative Law Judge Francis Young
wrote a ninety page opinion paper highlighting the
witness’ findings and agreed that MDMA should be
dropped to schedule III, IV or V because of its
potential medical value in mental health. Despite
the overwhelming evidence and the agreement by
Judge Young that the law should be changed, Judge
Young reinstated his original ban on MDMA,
leading to the permanent placement of MDMA in
Schedule I of the Controlled Substances Act in
1986 (Stafford 1992, p. III-63).
There is also evidence that the government
was aware of this inaccurate evaluation of LSD’s
danger because the CIA had conducted multiple
experiments on American and British military
personnel. From 1947 to 1977 the CIA had
conducted operations coded MKSEARCH,
MKOFTEN, MKCHICKWIT, MKULTRA,
MKDELTA, and MK NAOMI (General Council of
the Department of Defense 1977). Their goal was
to use LSD as a covert weapon to cause brain
damage or permanent insanity to the enemy. Their
other goal was to use LSD as a mind control agent
or torture device for prisoners in order to obtain
information (Greenberg 2010, p. 164) (National
Geographic Documentary 2009). It would have
been the perfect weapon because a 25 microgram
drop (the size of two salt grains) of this colorless
and odorless fluid anywhere on the skin could
cause the effects. One ounce is enough to dose 300
thousand people. The CIA was unable to achieve
their goals of weaponizing LSD. They were unable
to control minds or cause permanent insanity by
dosing personnel. Instead of being controlled or
damaged, the men had fits of laughter and an
enjoyment for the nature environments they were in
(National Geographic Documentary 2009).

ancient India, peyote used by Native American
tribes, rituals by Aztec shamans, ritual use by
peoples throughout Mexican history, ceremonies of
the ancient Greeks, and use of ayahuasca in modern
Brazil (Nichols 2003, p. 133). Psychedelics were
popular for philosophy development and religious
use because of their ability to induce states of
altered perception. These substances were not
considered “drugs” in these cultures. To find
references to use in literature, it is important to look
at key words such as “fruit of the gods,” “divine
fruit,” or “flesh of the gods.”
The science of psychedelics became popular
after new scientific methods for synthesizing
psychoactive substances became available and new
techniques for studying them. MDMA was first
synthesized in 1912 by Merck chemist Anton
Kollisch (Ecstasy Rising 2004).
MDMA hadn’t been ingested at that point, so there
was no indication of its potential effects. Soon after
Albert Hoffman synthesized LSD at the Sandoz
pharmaceutical laboratory in 1938, scientific
interest began to peak in psychedelics. Hoffman
had accidentally ingested a small amount and
experienced the world’s first LSD trip (National
Institute on Drug Abuse 2001). By the 1965 more
than a thousand peer-reviewed research articles
detailed the use of psychedelic compounds for
medical purposes. Promising therapeutic effects
were reported in over 40,000 subjects who had each
used LSD in multiple sessions (Vollenweider and
Kometer 2010, p. 1) (Nichols 2003, p 162)
(Stafford 1992, p. 40-44). At the same time,
recreational use was rampant, having been made
popular by Leary and his associates (Stafford 1992,
p. 51). The suicide of Diane Linkletter, daughter of
the entertainer Art Linkletter, after taking LSD was
one of the major sparks that allowed the passing of
the Controlled Substance Act of 1970 which put all
psychedelics on the schedule I list. The media had
argued that Diane had no personal problems, and it
was the drug that caused the suicide. While alive
she was portrayed as a well-educated, Christian,
white woman with no prior drug use or symptoms
of depression (Baum 1997, p. 25) (Greenberg 2010,
p. 256). Rampant use of ecstasy in the 1980s lead to
the adding of MDMA to schedule I in 1985. The
Controlled Substance Act and the war on drugs
interrupted all research until the 1990s, where
research began to make a slow comeback.
A recent resurgence of research on these
substances questions the validity of their schedule I
classification. Media outlets such as World Report
and the New York Times have expressed excitement

Historical Uses of Psychedelics
Psychedelics occur naturally in both animals
and plants. They have played a significant role in
the development of philosophy and religious
thought in earlier cultures. Well documented
examples of psychedelic use include the soma of
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about the psychedelic assisted psychotherapies for
the treatment of anxiety, depression, post-traumatic
stress disorder, obsessive compulsive disorder,
addiction, and more. Tom Roberts, professor of
educational psychology at Northern Illinois
University, notes that “What we see now is the
[US] FDA making decisions based on data rather
than politics” (Morris 2008, p. 1491). Universities,
among them Johns Hopkins, Purdue University,
University of Arizona, Harvard, New York
University, and U.C.L.A, are obtaining federal
permission to study these substances, leading the
way in the United States. Non-profit groups such as
the Heffter Research Institute and the
Multidisciplinary Association for Psychedelic
Studies (MAPS) are also contributing (Tierney
2010).

necessary pharmacology to initiate or maintain
dependence (Nichols 2003 p. 134) (Studerus et al.
2010 p. 14). Results of a clinical study involving
227 psilocybin sessions with 110 subjects
conducted between 1999 and 2008, indicate that
“carefully monitored administration of psilocybin
to healthy volunteers within an experimental setting
does not increase the risk of subsequent abuse of
psilocybin or other illicit drugs (Studerus et al.
2010, p. 14).” These results are in line with another
long term study involving LSD. In a ten year follow
up of 247 subjects who received LSD in an
experimental or therapeutic setting, most subjects
reported discontinuing or reducing their
hallucinogen drug use. Use of hallucinogens tends
to be less frequent or discontinued over time.
Regular use is unlikely for several reasons.
Tolerance develops at a rapid rate (Studerus et al
2010, p. 14). Hallucinogens, when taken for a
second consecutive day, do not give the user the
normal effects. Subjects in the psilocybin study
reported the effects as being tired. They were glad
to regain their normal state of consciousness and
needed time to recharge. Furthermore,
hallucinogens do not produce the pleasurable
effects of addictive drugs such as escape, euphoria,
anxiety relief, increase of self-esteem, etc (Studerus
et al. 2010, p. 14).

Research Supporting Lowering LSD, Psilocybin,
and MDMA from Schedule I
Since the 1960s, public service announcements
have been making false claims about LSD and
Psilocybin that had not been confirmed by ethical
scientific research, frightening drug effects ranging
from schizophrenia, chromosome damage, birth
defects, and murder to suicide (National
Geographic Documentary 2009). False claims
about MDMA have included irreversible brain
damage, Parkinson’s after one pill, and holes in the
brain (Ecstasy Rising 2004). Current leaders in this
field, who have performed ethical clinical trials
with animals and humans, disagree with these
claims. Their research also shows that these
hallucinogens meet none of the criteria required for
schedule I designation.

2) There is a lack of safety for use of the drug
under medical supervision.
“Hallucinogens are generally considered to be
physiologically safe molecules whose principle
effects are on consciousness (Nichols 2003, p.
134).” They do not have harmful physiological
effects. Hallucinogens are not toxic to any
mammalian organ systems and there is no evidence
to suggest that they damage any human organs.
“Hallucinogens do not cause lifethreatening changes in cardiovascular, renal, or
hepatic function because they have little or no
affinity for the biological receptors and targets that
mediate vital vegetative functions (Nichols 2003, p.
134).” Dr. James Gill, Deputy Chief Medical
Examiner in New York City, conducted a three
year study in the early 2000s to see how many
deaths in New York City were related to MDMA
toxicity. He looked at all the autopsies that were not
related to any natural causes of death. Out of
19,000 autopsies, only 22 subjects had MDMA in
their system. Of these 22 subjects, only two of the
deaths could be attributed to ecstasy alone. This
study was conducted at a time when statistics from

1) The drug has a high potential for abuse.
Hallucinogens do not engender drug
dependence or addiction and are not considered
reinforcing substances. They don’t produce drugseeking behavior or physical withdrawal symptoms
(Nichols 2003, p. 134) (Studerus et al. 2010 p. 2).
The scientific community argues that dependence
liability in a drug stems from the ability to affect
dopaminergic (DA) transmission. “Nearly all
hallucinogens lack the affinity either for DA
receptors or for the DA uptake transporter and
therefore do not directly affect DA
neurotransmission (Nichols 2003, p 134).” There
are no literature reports of successful attempts to
train animals to self-administer hallucinogens,
indicating that these drugs do not possess the
253
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the DEA reported New Yorkers using
approximately 110 million doses of ecstasy
(Ecstasy Rising 2004).
The primary effect of administering
hallucinogens to subjects is psychological. LSD
and psilocybin can induce disturbing experiences.
They can also catalyze an onset of psychosis or
depression, which has led (in some cases) to
suicide. However, these drugs do not appear to
produce illness in people who are not predisposed
to those illnesses (Nichols 2003, p. 135). Psychosis
and depression were catalyzed only in people
having a genetic predisposition. The actual
numbers of occurrences for recreational users are
also low. A search of Medline in 2003 by Dr.
Nichols for cases of LSD-induced psychosis
yielded three reports in the previous 20 years
(Nichols 2003, p. 135). According to the 2006
National Study on Drug Use and Health,
approximately 23 million people (9.5 percent of the
population) over the age of twelve had used LSD in
their lifetime.
Risks can be avoided in ethical and
responsible medical settings. Bad trips can be
treated with “talk-down” therapy and
administration of benzodiazepines (Nichols 2003,
p. 135). Data from the psilocybin study
demonstrate safety and tolerability in both the short
term and long term with 227 psilocybin
administrations. There is no indication of
persisting perception disorders, prolonged
psychosis, or other long-term impairments of
functioning. A small proportion of “bad trips,”
were resolved by providing interpersonal support.
The team concluded “that psilocybin administration
to healthy, high functioning, and well-prepared
subjects in a responsible clinical or research setting
is generally well tolerated and that future studies
using this important research tool are justified
(Studerus et al. 2010, p. 16).” The administrations
were well tolerated, producing positive outcomes.
The team concluded that hallucinogenic drugs used
under controlled and supportive conditions can lead
to,
“Sustained positive changes in personality,
attitudes and values, particularly in those
subjects who have experienced profound
personal insights and transcendent or mystical
experiences. Among the most often reported
are more self-understanding, more tolerance of
others, less egocentricity, a less materialistic
and aggressive orientation, and more
appreciation of music, art, and literature
(Studerus et al. 2010, p. 14).”

Much contradictory research that emerged during
the war on drugs neglected two very important
concepts regarding hallucinogens. The first is that
hallucinogens are not predictable like other central
nervous system drugs. They do not have the same
effects every time because primary determinants of
subject experience are expectations (“set”) and
environment (“setting”) (Nichols 2003, p. 137)
(Greenberg 2010, p. 164). Hallucinogens do not
directly cause any behaviors or feelings. They
amplify the thoughts and emotions of the user and
are completely vulnerable the user’s “set” and
“setting.” A negative “set” and “setting” can result
in a “bad trip” or a disturbing experience. If a
clinical or research setting creates a positive “set”
and “setting,” the experience of the user can be
sublime. Early research supporting the current
scheduling of hallucinogens used a very negative
“set” and “setting” for the subjects. Subjects were
administered the drugs in very rigid, mechanical,
and frightening settings. They were strapped
down to a bed to be poked and prodded with tools
(National Geographic Documentary 2009). The
CIA also conducted unethical experiments by
dosing military soldiers without their knowledge or
consent. This led to a very small percent of soldiers
committing suicide via jumping out of windows
because they falsely believed they became
permanently insane (Greenberg 2010, p. 164). It
was the situation which elicited negative reactions
from the patients, not the drug itself. These
situations can be controlled. Secondly, different
doses produce different qualitative effects (Nichols
2003, p. 137).
Increasing or decreasing dosage does not
simply change the amplification of the effects.
There are different thresholds for different tiered
effects. For example, there is a certain dose
required for people to hallucinate on LSD and
psilocybin. If the dose is lower than that threshold,
the subject will not have hallucinations. This is
valuable because the patient can be given a dose
that can provoke the emotional and perceptive
effects without causing uncomfortable
hallucinations. This concept was neglected in
research aimed to see if hallucinogens could be
safely administrated.
3) The drug has no currently accepted medical
use in the United States.
LSD, Psilocybin, and MDMA each have their
own unique medical applications. They have a
cross tolerance and several shared effects, but their
254
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subtle differences in chemical structure cause them
to have unique effects, and thus a diversity of
medical applications. LSD and psilocybin are
known as Classical Hallucinogens. Classical
Hallucinogens have a high affinity for serotonin (5HT2A) receptors. MDMA does not have the same
affinity and is not considered a Classical
Hallucinogen. There are several potential medical
applications for administration of these three
hallucinogens to patients in order treat illness. The
illnesses which might be effectively treated with
hallucinogens currently have few highly effective
treatments available which also include harmful
side effects, thus necessitating this new innovative
research. There is also valuable information that
can be obtained about cognitive neuroscience by
studying the chemical interactions in the brains of
healthy subjects under the influence of Classical
Hallucinogens.

accomplished in approximately two ninety minute
sessions (Multidisciplinary Association for
Psychedelic Studies 2005, p. 9). The drug assisted
session will be longer than a typical session. It will
be multiple hours; depending on which drugs are
used and how long the effects from the
dosage is. After the session, it is beneficial for there
to be drug-free follow up sessions. All three drugs
of interest, along with other hallucinogens, have
special qualities for assisting therapy.
MDMA Assisted Psychotherapy
Preliminary trials with MDMA assisted
psychotherapy have had very high rates of success
with treating posttraumatic stress disorder.
“Posttraumatic stress disorder (PTSD) is a
debilitating anxiety disorder characterized by reexperiencing, hyperarousal and avoidance
symptoms, and is a major worldwide public health
problem (Mithoefer et al. 2010, p. 1).” “Patients
with PTSD are prone to extremes of emotional
numbing or overwhelming anxiety, and often have
a narrow window between thresholds of under and
over-arousal (Mithoefer et al. 2010, p. 1).”
According to the 2005 Multidisciplinary
Association for Psychedelic Studies (MAPS)
handbook,
“MDMA can attenuate the fear response and
decrease defensiveness without blocking
access to memories or preventing a deep and
genuine experience of emotion. Participants
are able to experience and express fear, anger,
and grief with less likelihood of feeling
overwhelmed by these emotions. MDMA
seems to engender awareness that such
feelings arise as an important part of the
therapeutic process. In addition, feelings of
empathy, love, and deep appreciation often
emerge, along with a clearer perspective of the
trauma as a past event and a heightened
awareness of the support and safety that exists
in the present. Hence, the goal of MDMAassisted therapy in treating PTSD is to enable
the participant to restructure his/her
intrapsychic realities and develop a wider
behavioral and emotional repertoire with
which to respond to anxiogenic stimuli.”
Many therapists who have experience performing
MDMA assisted psychotherapy claim that it could
accomplish what would take years of therapy in one
session (Baum 1997, p. 212) (Greenberg 2010, p.
154). An example of feedback from a patient is that
the drug helped her

Clinical Applications of Psychedelics
Psychedelic Assisted Psychotherapy
The concept for the technique of psychedelic
assisted psychotherapies is completely new.
Psychedelic assisted psychotherapy involves using
hallucinogens to put patients in an altered mental
and emotional state which would make a therapy
session more effective. Dr Roland Griffiths of the
School of Medicine at Johns Hopkins University
describes it as,
“Not about taking psilocybin or other
compounds multiple times. It’s about
orchestrating, if you can, a single profound
transformative experience; that then results in
an unfolding of behavioral change over time
(National Geographic Documentary).”
These sessions are only meant to happen once or
very few times and yield results of positive long
term behavioral change. The whole process has
several phases. First, the subject must be fully
diagnosed by a licensed professional. A review of
the subject’s background and diagnoses will need
to be analyzed to see if the subject has the
necessary prerequisites to safely take the drugs
(Multidisciplinary Association for Psychedelic
Studies 2005, p. 7). The subjects must then have
intense preparation before the psychedelic assisted
session (Vollenweider and Kometer 2010, p. 4).
The therapist must form a strong therapeutic
alliance, create a safe psychological and
physiological space, and prepare the participant
mentally for the experience. These can be
255
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confront memories of a rape she suffered, which
helped her end periods of depression in panic. She
told Newsweek, “not only did MDMA enable me to
recover my sanity, it enabled me to
recover my soul” (Baum 1997, p. 212). MDMA
assisted psychotherapy is primarily being used for
PTSD, however it has also shown promise in
couple’s therapy and mood and anxiety disorders.
MDMA, while classified as a hallucinogen and
psychedelic, does not cause psychotic-like states or
hallucinations like LSD or psilocybin.
Possible theories about the chemical
mechanism for MDMA are that MDMA releases
serotonin, stimulates the serotonin (5-HT2)
receptor, and increases the neurohormones
oxytocin, prolactin and cortisol. The mood and
perception lifts are caused by the serotonin release
(Mithoefer et al. 2010, pg. 3). “Findings suggest
that oxytocin is involved in affiliation, trust, and
accurate perception of emotion, so elevated
oxytocin might help participants form a therapeutic
alliance and revisit traumatic experiences in an
emotionally engaged state (Mithoefer et al. 2010, p.
3).” It was also found that oxytocin reduced
activation of the amygdale in humans, which is
responsible for fear emotions. A recent study also
found that elevation of oxytocin was associated
with greater sociability and gregariousness
(Mithoefer et al. 2010, p. 3).

improvements were improved mood, reduced fear
of death, and reduction in the amount of painrelieving medication required. Half of patients
reported dramatic improvement and profound
experiences (Nichols 2003, p. 163). Dr. Charles
Grob and his assistant Alicia Danforth conducted
an end of life study at Harbor UCLA Medical
Center which involved giving psilocybin assisted
psychotherapy to twelve terminally ill patients.
Terminally ill patients can be overwhelmed with
anxiety and fear about their upcoming death. They
also are typically on a lot of pain medication and
are in medical environments which restrict them
from appreciating life. Before dying, the patients
reported positive mood shifts and increased
acceptance of death. They had mended
relationships and were able to spend quality time
with their families (National Geographic
Documentary 2009).
There are several theories for possible
mechanisms to explain how classic hallucinogens
improve therapy. Scientists estimate that the brain
takes in eleven million bits of information per
second; however, the brain can only process about
two hundred bits at a time. To handle that amount
of information, the brain must filter out information
that is not critical. It does this by connecting new
information to preconceived concepts so that it
does not have to analyze all of it (National
Geographic 2009). Dr. Torsten Passie’s “Hollow
Mask Study” at the Hannover Medical School in
Germany concluded that schizophrenics and
subjects intoxicated by LSD do
not process information in that same way. The
filters are lifted and the ability to connect new
information to preconceived concepts is
temporarily suspended. This means psychedelics
temporarily de-condition the mind, resulting in the
ability to take in more information, more sensory
impression, more emotional impression, more
visual impression, and more access to parts of the
mind (National Geographic Documentary 2009).
This allows the LSD user to approach problems in a
more genuine and open minded way that neglects
socially conditioned behaviors or roles. The
increased mind power and stimulation comes from
the increased activity of the serotonin (5-HT2A)
receptor.
Activation of serotonin (5-HT2A) receptors
initiates complex chemical reactions in the prefrontal cortex. LSD and psilocybin have such a
similar shape to serotonin molecules that they are
able to fit in the receptor like a lock and key.
Serotonin (5-HT2A) receptors are located on the

LSD and Psilocybin Assisted Psychotherapies
LSD and psilocybin have different effects than
MDMA because they agonize different serotonin
receptors. They both primarily agonize the
serotonin (5-HT2A) receptor which plays a major
role in their medical applications. Researchers
believe LSD and psilocybin may be useful in
treating depression, anxiety, and Obsessive
Compulsive Disorder (OCD) as an adjunct to
therapy. Several universities, including New York
University, Johns Hopkins University, and
University of California have had a lot of success
with treating anxiety and depression in
terminally ill cancer patients (Vollenweider and
Kometer 2010, p. 3). Studies from the 1960s
concluded that LSD treatment resulted in improved
psychological adjustment in dying patients,
made them more responsive to their families and
environments, and enhanced their ability to enjoy
every-day life. Later studies at Spring Grove State
Hospital in Maryland showed improvement in
about two-thirds of the cancer patients who had
received LSD. Some of these reported
256
https://knightscholar.geneseo.edu/proceedings-of-great-day/vol2011/iss1/25

6

Demosthenous: Psychedelic Research Resurgence

large glutamatergic pyramidal cells in the deep
cortical layers. The chemical reactions from
binding with the serotonin (5-HT2A) receptors
releases glutamate across the synapse, which then
activates the AMPA (α-amino-3-hydroxy-5-methyl4-isoxazole propionic acid) and NMDA (N-methyld-aspartate) receptors on the cortical pyramidal
neurons. In addition, LSD and psilocybin directly
activate the serotonin (5-HT2A) receptors located
on cortical pyramidal neurons. The synergy of
activating the serotonin (5-HT2A), AMPA, and
NMDA receptors on the cortical pyramidal neuron
results in the increased expression of brain-derived
neurotrophic factor (BDNF) (Gonzalez-Maeso and
Sealfon 2009, p. 227) (Vollenweider and Kometer
2010, p. 5). BDNF is a chemical that promotes the
growth and survival of neurons. A deficiency in
BDNF may impair the health of neurons and lead to
depression (Comer 2010, p. 250). Since serotonin
(5-HT2A) receptors are linked to the prefrontal
cortex, this means Classical Hallucinogens lead
to increased neuron strength in the prefrontal cortex
from the BDNF. Areas in the prefrontal cortex are
responsible for complex mental functions such as
cognition, mood, perception, self
control, and somatic awareness (Nichols 2003, p.
162). The increased effectiveness of therapy may
be derived from a boost of brain metabolism and
strength in these mental functions.

administered it three times over a fifteen day
period. For five of the six participants the
headaches were gone. All of the participants
reported that their quality of life had totally
changed (National Geographic Documentary2009).
The addition of a BROMO molecule to LSD
creates a molecule that is too big to fit in the
receptors that would normally trigger intoxication.
LSD-BROMO successfully relieves cluster
headaches in the same way other LSD molecules
do, except it has no hallucinogenic properties.
Despite displaying no hallucinogenic properties,
LSD-BROMO was added to schedule I and is
illegal in the United States; thus restricting research
and clinical trials. Since This trial, no further
clinical trials have been funded to administer LSD,
psilocybin, or non-hallucinogenic LSD-BROMO to
treat cluster headaches (National Geographic
Documentary 2009).
Understanding Cognitive Neuroscience through
LSD-Like Intoxication in Healthy Subjects
LSD-like hallucinogens, including psilocybin
but not MDMA, are psychotomimetic at high
doses; meaning they induces psychotic like
episodes (Gonzalez-Maeso and Sealfon 2009, p. 2)
(Nichols 2003, p. 162). There are a wide variety of
hallucinogens that mimic different types of
psychotic symptoms and disorders. The effects are
contingent on how the molecules are shaped and by
what receptors they either agonize or antagonize.
LSD in particular mimics the positive symptoms of
schizophrenia (hallucinations and thought
disorder). Psychotomimetic hallucinogens can be
used as tools for understanding neuronal basis of
psychiatric disorders, understanding a psychotic
experience, and finding a cure for those psychiatric
disorders (Vollenweider and Kometer 2010, p.1).
Franz Vollenweider uses neuroimaging technology
at the University Hospital of Psychiatry in Zurich to
map brains on psychedelics. His data shows that a
brain on hallucinogens looks the same every time
(National Geographic Documentary 2009). This
means clinical trials with psychotomimetics are
reliable to be analyzed and compared for
conclusions.
Schizophrenia is very difficult to treat and
learn about because some of the symptoms make
fruitful communication between the patient and
doctor impossible. Formal thought disorders, loose
associations, derailment, poverty of speech,
avolition, and social withdrawal make verbal
communication very difficult (Comer 2010, p.

Administration to Patients: LSD and Psilocybin for
Treatment of Cluster Headaches
John Halpern’s research, at the McLean
Hospital at Harvard Medical School, illustrates that
LSD and psilocybin may have a high success rate
for reliably treating cluster headaches. Cluster
headaches are severely painful and debilitating
headaches that reoccur. Scientists do not fully
understand what causes cluster headaches, but they
know it is related to blood vessels, nerves and
neurochemistry. There is no cure and few
treatments. The available treatments, including
oxygen and/or medication, are minimally effective.
The mechanism is unknown, but LSD and
psilocybin seem to be highly effective in relieving
or eliminating cluster headaches. A survey by
Halpern indicated that for 53 subjects, psychedelics
prevented or stopped cluster headaches more
reliably than medication. Halpern and his
colleagues at the Hannover Medical School in
Germany launched a clinical trial on six subjects
with cluster headaches. The team developed a nonpsychedelic form of LSD, LSD-BROMO, and
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462). LSD-like hallucinogens can help researchers
and doctors learn more about the schizophrenic
experience by taking it themselves or performing
clinical trials. Once the subject is sober, they will
have their previous mental capacity and intelligence
restored and be able to articulate their experience in
a more accurate way than a patient with a
permanent psychopathology. Dr. Charles Nichols,
Geneticist from the LSU Health Sciences Center,
also believes “by understanding how LSD produces
its effect at the molecular and genetic level, we
could potentially understand mechanisms
underlying diseases like psychosis that have very
similar overlapping behaviors (National
Geographic Documentary 2009).” By
understanding the neurochemical and genetic
causes of psychosis, psychopharmacologists could
potentially be able to create drugs that negate those
causes in order to treat psychosis more effectively.
One possible problem with finding treatments
for certain psychotic disorders, such as
schizophrenia, is that they are uniquely human
disorders (Gonzalez-Maeso and Sealfon 2009, p.
1). This means there are no animal models to do
tests on. Animal test subjects are crucial because
scientists can perform tests on them that would be
unethical for human subjects. They can be bred to
control for variables and provide a larger supply of
test subjects. Hallucinogens fix this problem
because they give opportunities to test
schizophrenic-like mice. According to Dr. Nichols,
LSD induced mice display human symptoms of
schizophrenia. This gives him the ability to study
brains of schizophrenic mice and test potential
treatments on them (National Geographic 2009).
They can induce mice with schizophrenic episodes
and test anti-psychotics to see if they bring the mice
back to a normal state of health.
Hallucinogens agonize and antagonize various
serotonin receptors, among other neurotransmitters.
The serotonin receptors in particular that
hallucinogens interact with affect complex parts of
the human brain, including much activity in the
prefrontal cortex and interconnecting pathways
between the cerebral cortex and limbic systems
(brain regions implicated in pathophysiology of
many mental disorders) (Gonzalez-Maeso and
Sealfon 2009. p 228). Pathology relating to mood
and anxiety is associated with an imbalance or
abnormal functioning of serotonin chemical
reactions. Thus, testing and understanding the
mechanisms of hallucinogens may lead to
important clues for the basis of psychosis. The
results obtained from the mechanism of Classical

Hallucinogens may provide efficient approaches for
the rational design and testing for new types of
antipsychotic drugs (Gonzalez-Maeso and Sealfon
2009, p. 225). This also means experimental use
with hallucinogens can be a great aid for mapping
out the brain and further understanding the
prefrontal cortex, pyramidal cells, serotonin,
glutamate NMDA, AMPA, and BDNF interactions.
Methodology
Semi-structured interviews were conducted
with a snowball sample of subjects to learn about
their experiences with MDMA, LSD and
psilocybin. The subjects were recruited privately
through networking within the drug using
community. Six public liberal arts College students
were selected because of their high level of
experience with the substances of interest. Five of
the subjects were male and one was female. The
goal of the interviews was to evaluate if the effects
of MDMA, LSD, and psilocybin were recreational
or entheogenic. The operational definition for
“recreational experience” is experiences that cause
altered physical and mental effects during
intoxication. However, after the substance has been
processed and excreted from the body, the subject
retreats to their previous physical and mental states
prior to intoxication. The operational definition of
“entheogenic experience” is long term
transformative effects on personality, spirituality,
cognitive state, emotional state, and perception of
one’s self after intoxication.
The interviews ranged from twenty minutes to
an hour in length. The interviews were conducted at
each subject’s home for comfort and privacy. To
prevent coding bias, the interviews were recorded
on a handheld recorder and later transcribed. The
subjects gave verbal consent on the recorder. The
recordings were deleted after transcription to
protect the subject’s from being identified by their
voice. No names or information that could be used
to identify the subjects were used. The interviews
had a pre-set list of questions; however, the
subjects had freedom to discuss details beyond the
scope of the pre-set questions. The subjects were
asked questions about three different phases related
to their drug use. They were asked questions about
their experiences leading up to their first time uses
with these drugs. They were asked questions about
the experiences and feelings while intoxicated by
these drugs. Finally they were asked about their
experiences and reflections after their intoxication
had ceased.
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The subjects had varying levels of experience
with each drug.

small groups and in environments where they felt
safe and comfortable.
Effects and Experiences While Intoxicated
Subject 5 used MDMA and LSD as party
drugs. She used them to enhance social
experiences. It enables her to connect with people
more easily and with more depth. “On ecstasy I just
love everyone.” The euphoria also amplifies the
pleasure of music, colors and dancing. She also
reported a greater connection with nature on LSD
and psilocybin. The effects of the
hallucinations were not as intense due to the
relatively low doses she used. She described her
environment as being “wavy” and “breathing.”
Since the effects were not too intense, they were
always very manageable. She claimed to feel very
safe and confident in her drug use.
Subjects 1,2,3,4, and 6 had different
experiences than subject 5. Their experiences were
more intense and more varied. They reported
having few negative moments in their experiences,
but they were always able to calm themselves or
each other down during those unfavorable intense
moments. Aside from those few moments, they
report overwhelmingly positive transformative
experiences. They were very introspective.
According to subject 4,
“Whatever your feeling becomes dramatic and
exaggerated and richer than you’ve ever
experienced before. You kind of see your dark
side and light side. You see your persona for
what it is; for all its sincerity and bulls***.
You see your shadow for what it is. You see
your entire personality almost from an outside
perspective and I think part of being on acid is
losing that sense of judgment of positive and
negative and ultimately coming to the
conclusion that this is who you are. And as far
as today goes, you’re not going to change it.
So you might as well embrace it.”
Subject 4 also reported the “[he] dance[s] across the
entire emotional spectrum, but [he] does it with the
volume turned all the way up.” He later said that he
has experienced a range from ecstatic bliss to
depressive nihilism.
Subject 1, when talking about LSD reported,
“The way I experience the world is that
everything is more beautiful. I’ll just see
something like a leaf with a dew drop on it and
just love the natural beauty of it. Everything
around just seems more vivid and I’m

Bar Chart: Subject’s estimate of experiences using
Psilocybin (left bars), MDMA (middle bars) and
LSD (right bars). Each subject had at least twelve
combined experiences with the drugs of interest.
All of the subjects reported doing some type of
research before having their first experience with
these hallucinogens. They approached these drugs
with skepticism and caution because of the negative
stigma associated with them. Each subject used
sources such as books, encyclopedias, friends who
had experience, and online sites for information
about what to expect and how to approach the
experience. All of the subjects mentioned using
erowid.com for anecdotes, information about
appropriate doses, and advice for activities to do
while intoxicated.
Subject 5 (female) appeared to have
recreational experiences while the rest of the
subjects appeared to have, for the most part,
entheogenic experiences. This can be explained by
their different habits of use. Subject 5 typically
took lower than average drug doses, which since
hallucinogens have different qualitative affects at
different dose levels, gave her less intense
effects compared to the other users. She used the
drugs to make regular recreational activities, such
as dancing to music, more enjoyable.
Subjects 1,2,3,4, and 6 used hallucinogens
differently than subject 5. They took higher doses
and created their own private ritual-like
experiences. They tended to avoid large social
situations; instead, they spent their experiences in
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generally pretty happy. I’ve never had a bad
trip.”
Subject 1 takes SSRIs, however, he reported a
better mood lift with acid. “If I could take acid once
a month, I could be content with the whole month.”
The enthogenic subjects not only experienced
introspective self-analyses, but also examined their
relationships with family and friends. They
reported that hallucinogens have been important
aids in repairing or strengthening relationships.
Four out of the five entheogenic users had specific
anecdotes on how hallucinogens played a positive
role in their relationships. Subject 1 reported,
“A couple of years ago I was having a fight
with my girlfriend and I just took a couple of
tabs of acid, probably not the best idea to do in
that situation. I just went alone and did acid
with a friend. It made me feel like, why am I
fighting with my girlfriend? I should just go
and make amends because it’s stupid. I kind of
felt love for everybody.”
Subject 2 had an elaborate intimate experience with
his significant other which he attributed
to MDMA. They both took MDMA at his house.
“She was nervous at first. As we were coming
up I comforted her and she became more
comfortable with the sensation. From that
point until we came down it was just heaven.
We laid around in my room in our underwear
and we just talked. We talked about each
other and who are some people important in
our lives. The whole experience centered
around her and I and we really connected. And
there are things that people say to each other,
or don’t say to each other rather. Like when
you say very emotionally charged things to
somebody you care about; sometimes you’re
apprehensive about overstating your
appreciation for them to avoid maybe
cheapening the relationship or feeling that you
have for them. I think MDMA really let us say
these things to each other and really mean it
and understand that the other meant it. Like I
said, sometimes you avoid saying these things
to avoid cheapening what they mean and other
times you simply don’t get around to saying it
them due to circumstances or timing or
whatever. It let everything out that needed to
come out. It was really instrumental in us two
making that connection.”
Subjects 3 and 6 talked about psilocybin
experiences that elicited strong positive emotional
feelings about family members. Subject 3 reported,

“One of my first experiences with psilocybin
was at a concert and I remember enjoying the
music very much. But at one point in the
concert, I had just stopped and found my mind
wondering and daydreaming. I was thinking
about the relationship I had with my mother at
the time. I didn’t particularly like the way the
relationship was going and so in the calm state
I was in I wondered, Why isn’t that better?
Why don’t I better that relationship?”
Subject 6 detailed one of his psilocybin
hallucinations and emotions associated with it.
“My next journey was with my girlfriend. We
were dressed like Adam and Eve in a forest.
We held each other and spiraled into the green
and blue corners of space and time. It wasn’t
erotic. It was a spiritual connection. I felt close
to her. I felt one with her. I thought about my
family. I connected with their spirits. Our
energies became one. There was no more
sadness. All problems ceased to exist. I met
my father and we were free.”
Post Experience Reflections
There were several common reflections among
the subjects. All of the subjects feel safe, secure
and confident with these drug experiences. They
are all open-minded to using these substances again
in the future. They are so confident in their
experience and understanding of the drugs that they
would feel comfortable recommending use to a
friend or loved one. All of the users also reported
having no regretted experiences on these
substances. They felt the negative moments had
value to their development and character.
The entheogenic users also had some common
sentiments. They felt that their experiences with
these drugs had a very positive impact on their
relationships, mood, outlook on life, and creativity.
They use these drugs primarily for spiritual and
emotional development. They did not use
frequently; rather, they decided to use at key
moments in their life where they were struggling,
had big decisions to make, or wanted to bond with
friends.
Conclusion
Hallucinogens have a long history of being
used by humans for spirituality and well-being. The
act of moving hallucinogens to schedule I with the
Controlled Substance Act was hasty and poorly
thought out. This decision interrupted much needed
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research into mental health and well-being. Current
projects offer data that supports the lowering of
hallucinogens from schedule I to a level that would
continue to prohibit recreational use, while
permitting research and medical use. There is
overwhelming evidence that hallucinogens do not
meet the criteria set by the Controlled Substance
Act to be ranked as schedule I. Hallucinogens have
a very low potential for abuse. They are one of the
least addictive drugs that exist. They can be safely
used in a medical situation because of a lack of
toxicity and addiction. With the appropriate dose,
set and setting, a licensed professional can create a
safe and controlled environment for patients to use
in a medical situation. The literature also shows
that there are many potential medical uses in the
United States from psychedelic assisted
psychotherapy for the treatment of mood and
anxiety disorder and Classical Hallucinogens for
the treatment of cluster headaches, to clinical trials
to aid in the creation of more efficient medications.
The research is in its preliminary stages and
has not had many large trials. Much work needs to
be done on understanding the mechanisms for how
the drugs affect the brain and behavior at the
molecular level. Success of preliminary studies
justifies larger scale double blind trials. Results
justify increased access to funding and permission
for research institutions to use these substances in
clinical trials.
The interviews support the literature and
illustrate that it may be possible to orchestrate
possible healthy and positive experiences with
these drugs. Recreational users may not always
give accurate insight or judgment about these drugs
because street drugs are un-regulated. The drug’s
purity is unknown to the recreational user. Despite
this flaw, the subjects interviewed did display
characteristics predicted by the literature. Subject
5’s description of how she feels on LSD is in line
with Dr. Passie’s conclusions from the “Hallow
Mask Studies.” It supported the mechanism by
which LSD takes off the filters and allows a person
to evaluate themselves or a situation in a new way.
This account also illustrated the significance of
“set” and “setting” because subject described how
he feels a whole range of emotions instead of the
same ones every time. All of the subjects displayed
how hallucinogens can be a positive influence on
mood. The anecdotes from Subjects 1, 2, 3, and 6
illustrated how hallucinogen helped them in their
relationships. This supports the hypothesis that
psychedelic assisted psychotherapy may be
effective in couples therapy or family therapy.

Research into techniques for psychedelic
assisted psychotherapy is imperative because they
may be faster, safer and more effective than
alternative methods used today; such as antidepressants and other medications. According to
Greenberg, anti-depressants fail to outperform
placeboes in clinical trials nearly half the time.
They appear to make a positive difference in
approximately 60 percent of the people who take
them, while having serious side effects such as
suicide (Greenberg 2010, p. 8). Mental health
patients need newer treatments that are more
effective, just as fast and without the serious
potential side effects that exist with current
medications.
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